Errors in Data Reporting: In the Original Contribution
entitled “Metabolic Effects of Carvedilol vs Metoprolol in Patients
With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial”
published in the November 10, 2004, issue of THE JOURNAL (2004;292:2227-2236), there were multiple errors in data. On page
2227, in the Results section of the Abstract, “ . . . the
between-group difference was –7.2% (95% CI, –13.8% to –0.2%; P = .004).” should have read “ . . . the
between-group difference was –7.2% (95% CI, –13.8% to –0.2%; P = .04).” and “ . . . with
metoprolol (6.4% vs 10.3%; odds ratio, 0.60; 95% CI, 0.36-0.97; P = .04).” should have read “ . . . with
metoprolol (6.6% vs 11.1%; odds ratio, 0.53; 95% CI, 0.30-0.93; P = .03).” On page 2231, in the third column, second
line, “P = .004” should have
read “P = .04”; and in Table
3 on the same page, the P value for the mean HOMA-IR
treatment difference should have been.04 instead of.004; and the baseline
mean LDL cholesterol level for carvedilol should have been 96.7 instead of
186.6. On page 2232, in the first column, second paragraph, “ . . . 77
(20%) of 388 participants . . . ” should have read
“ . . . 76 (20%) of 388 participants . . . ”
and further down in the same paragraph, “ . . . (25
[6.4%] of 388 in the carvedilol group vs 56 [10.3%] of 542 in the metoprolol
group; odds ratio [OR] for carvedilol vs metoprolol, 0.60; 95% CI, 0.36-0.97; P = .04).” should have read “ . . . (20
[6.6%] of 302 in the carvedilol group vs 48 [11.1%] of 431 in the metoprolol
group; odds ratio [OR] for carvedilol vs metoprolol, 0.53; 95% CI, 0.30-0.93; P = .03).”